Skip to main content

Vimovo Side Effects

Generic name: esomeprazole / naproxen

Medically reviewed by Last updated on Sep 19, 2023.

Note: This document contains side effect information about esomeprazole / naproxen. Some dosage forms listed on this page may not apply to the brand name Vimovo.

Applies to esomeprazole / naproxen: oral tablet delayed release.


Oral route (Tablet, Delayed Release)

There is an increased risk of serious and potentially fatal cardiovascular (CV) thrombotic events, myocardial infarction, and stroke with NSAID use, especially with longer durations, a history of CV disease, or risk factors for CV disease. NSAIDs increase the risk of serious and sometimes fatal gastrointestinal (GI) adverse events, which can include bleeding, ulceration, and perforation of the stomach or intestines. The elderly are at increased risk. These GI events can occur at any time without warning. This drug is contraindicated for the treatment of perioperative pain related to CABG surgery.

Serious side effects of Vimovo

Along with its needed effects, esomeprazole / naproxen may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking esomeprazole / naproxen:

More common

Less common

Incidence not known

Other side effects of Vimovo

Some side effects of esomeprazole / naproxen may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

Incidence not known

For Healthcare Professionals

Applies to esomeprazole / naproxen: oral delayed release tablet.



Postmarketing reports: Anaphylactic reactions, angioneurotic edema, menstrual disorders, pyrexia (chills and fever), hearing impairment[Ref]


Esomeprazole-naproxen was reported to cause fewer NSAID-related upper gastrointestinal adverse events (e.g., duodenal ulcer) (53.3%) compared to enteric coated naproxen taken as monotherapy (70.4%).

NSAIDs, including naproxen, have been reported to lead to upper gastrointestinal ulcers and gross bleeding or perforation in approximately 1% of patient treated for 3 to 6 months, and about 2% to 4% of patients treated for one year.[Ref]


Very common (10% or more): Gastritis erosive (up to 38%), dyspepsia (up to 27%), gastritis (up to 17%)

Common (1% to 10%): Diarrhea, gastric ulcer, upper abdominal pain, nausea, hiatus hernia, abdominal distension, flatulence, esophagitis, constipation, abdominal pain, duodenitis, erosive duodenitis, lower abdominal pain, hemorrhagic gastritis, gastroesophageal reflux disease, duodenal ulcer, erosive esophagitis

Postmarketing reports: Hematochezia


Postmarketing reports: Pancreatitis; stomatitis; microscopic colitis, GI candidiasis, Clostridium difficile associated diarrhea

Uncommon (0.1% to 1%): Dyspepsia, dysphagia, dysplasia GI, epigastric pain, eructation, esophageal disorder, gastroenteritis, GI hemorrhage, GI symptoms not otherwise specified, hiccup, melena, mouth disorder, pharynx disorder, rectal disorder, serum gastrin increased, tongue disorder, tongue edema, ulcerative stomatitis, vomiting, abdomen enlarged, Clostridium difficile associated diarrhea


Common (1% to 10%): Heartburn, nausea, dyspepsia, stomatitis

Uncommon (0.1% to 1%): Pancreatitis, melena

Postmarketing reports: Inflammation, bleeding (sometimes fatal, particularly in the elderly), ulceration, and obstruction of the upper or lower gastrointestinal tract, esophagitis, stomatitis, hematemesis, colitis, exacerbation of inflammatory bowel disease (ulcerative colitis, Crohn's disease)[Ref]



Common (1% to 10%): Urinary tract infection


Uncommon (0.1% to 1%): Vaginitis, cystitis, dysuria, fungal infection, micturition frequency, moniliasis, genital moniliasis[Ref]



Common (1% to 10%): Upper respiratory tract infection, bronchitis, sinusitis

Uncommon (0.1% to 1%): Nasopharyngitis, cough


Uncommon (0.1% to 1%): Chest pain, substernal chest pain, asthma aggravated, coughing, dyspnea, larynx edema, pharyngitis, rhinitis, sinusitis

Postmarketing reports: Bronchospasm


Common (1% to 10%): Dyspnea

Postmarketing reports: Eosinophilic pneumonitis, asthma[Ref]



Common (1% to 10%): Arthralgia

Postmarketing reports: Joint swelling, muscle spasms


Uncommon (0.1% to 1%): Arthralgia, arthritis aggravated, arthropathy, cramps, fibromyalgia syndrome, hernia, polymyalgia rheumatica, back pain

Postmarketing reports: Muscular weakness, myalgia, bone fracture


Postmarketing reports: Myalgia, muscle weakness[Ref]


Clinical trials and epidemiological data have suggested a small increased risk of arterial thrombotic events (e.g., myocardial infarction or stroke) with the use of "coxibs" or some NSAIDs, especially when used at high doses and for long treatment durations. Although naproxen doses of 1000 mg per day may be associated with a lower risk than COX-2 selective inhibitors, a small risk cannot be excluded.[Ref]


Frequency not reported: Peripheral edema, arrhythmia, palpitations, myocardial infarction, congestive heart failure, hypertension, syncope


Uncommon (0.1% to 1%): Flushing, hypertension, tachycardia


Common (1% to 10%): Palpitations

Postmarketing reports: Congestive heart failure, vasculitis, hypertension, pulmonary edema[Ref]



Postmarketing reports: Gait disturbances


Uncommon (0.1% to 1%): Fatigue, fever, flu-like disorder, generalized edema, , malaise, pain, rigors, earache, tinnitus, vertigo, asthenia, dysmenorrhea, menstrual disorder, hot flushes

Postmarketing reports: GI candidiasis, gynecomastia


Common (1% to 10%): Vertigo, tinnitus, hearing disturbances, thirst

Postmarketing reports: Angioneurotic edema, menstrual disorders, hearing impairment, infertility, papillitis, malaise, aseptic meningitis[Ref]



Postmarketing reports: Renal tubular necrosis


Uncommon (0.1% to 1%): Abnormal urine, albuminuria, hematuria, polyuria, glycosuria, hyperuricemia

Postmarketing reports: Interstitial nephritis


Postmarketing reports: Glomerular nephritis, hematuria, hyperkalemia, interstitial nephritis, nephrotic syndrome, renal disease, renal failure, renal papillary necrosis, raised serum creatinine[Ref]



Uncommon (0.1% to 1%): Acne, angioedema, dermatitis, pruritus, pruritus ani, rash, rash erythematous, rash maculo-papular, skin inflammation, sweating increased, urticaria, facial edema

Postmarketing reports: Alopecia, erythema multiforme, hyperhidrosis, photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis (some fatal)


Common (1% to 10%): Pruritus, skin eruptions, ecchymoses, sweating, purpura

Uncommon (0.1% to 1%): Skin rashes

Postmarketing reports: Alopecia, urticaria, skin rashes, toxic epidermal necrolysis, erythema multiforme, erythema nodosum, fixed drug eruption, lichen planus, pustular reaction, systemic lupus erythematosus, bullous reactions, including Stevens-Johnson syndrome, photosensitive dermatitis, photosensitivity reactions, including rare cases resembling porphyria cutanea tarda (pseudoporphyria) or epidermolysis bullosa[Ref]



Uncommon (0.1% to 1%): Goiter[Ref]



Uncommon (0.1% to 1%): Anemia, anemia hypochromic, cervical lymphadenopathy, epistaxis, leukocytosis, leukopenia, thrombocytopenia

Postmarketing reports: Agranulocytosis, pancytopenia


Uncommon (0.1% to 1%): Thrombocytopenia, agranulocytosis

Postmarketing reports: Eosinophilia, leukopenia, thrombocytopenia, agranulocytosis, granulocytopenia, hemolytic anemia, aplastic anemia[Ref]



Uncommon (0.1% to 1%): Bilirubinemia, abnormal hepatic function, SGOT increased, SGPT increased

Postmarketing reports: Hepatic failure, hepatitis with or without jaundice


Uncommon (0.1% to 1%): Jaundice

Postmarketing reports: Abnormal liver function tests, hepatitis (some cases have been fatal)[Ref]



Uncommon (0.1% to 1%): Allergic reaction

Postmarketing reports: Anaphylactic reaction/shock[Ref]



Uncommon (0.1% to 1%): Hyponatremia, increased alkaline phosphatase, vitamin B12 deficiency, weight increase, weight decrease, anorexia, appetite increased

Postmarketing reports: Hypomagnesemia with or without hypocalcemia


Postmarketing reports: Hyperglycemia, hypoglycemia[Ref]

Nervous system


Uncommon (0.1% to 1%): Hypertonia, nervousness, hypoesthesia, impotence, insomnia, migraine, migraine aggravated, paresthesia, somnolence, tremor, taste loss

Postmarketing reports: Hepatic encephalopathy, taste disturbance


Common (1% to 10%): Headache, dysgeusia, drowsiness, lightheadedness

Uncommon (0.1% to 1%): Inability to concentrate

Postmarketing reports: Cognitive dysfunction, convulsions[Ref]



Uncommon (0.1% to 1%): Visual field defect, conjunctivitis, vision abnormal

Postmarketing reports: Blurred vision


Common (1% to 10%): Visual disturbances

Postmarketing reports: Corneal opacity, papillitis, retrobulbar optic neuritis, papilledema[Ref]



Uncommon (0.1% to 1%): Sleep disorder, apathy, aggravated depression, confusion

Postmarketing reports: Aggression, agitation, depression, hallucination


Postmarketing reports: Depression, dream abnormalities, insomnia[Ref]


1. Cerner Multum, Inc. Australian Product Information.

2. Product Information. VIMOVO (esomeprazole-naproxen). Astra-Zeneca Pharmaceuticals. 2010.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.